Summary
We have compared the disposition of oral paracetamol (1.0 g t.d.s. for 10 days) in 6 healthy volunteers and 6 conservatively-managed patients with chronic renal failure (mean plasma creatinine 451 μmol·l−1). Blood was sampled daily for 10 days before the morning dose of paracetamol.
Each day the pretreatment plasma concentrations of paracetamol were higher in the renal failure patients than in the volunteers, with mean values over the 10 days of 3.1 and 1.1 mg·l−1 respectively. The mean daily plasma concentrations of the sulphate and glucuronide conjugates of paracetamol were markedly higher in the renal failure group and apparent steady-state concentrations of about 25 and 85 mg·1−1 were reached on the 2nd and 6th days respectively. The mean steady-state plasma concentrations of the glucuronide conjugate on the 7th to 10th days of treatment were positively correlated with the plasma creatinine concentration (r=0.97), but this relationship did not hold for the sulphate conjugate. Cysteine and mercapturate conjugates could only be detected in one patient.
Predictions of steady-state concentrations based on previous studies with single doses of paracetamol in renal failure patients were remarkably accurate for the glucuronide but not for the sulphate conjugate.
These results are consistent with some extra-renal elimination of retained paracetamol conjugates in patients with chronic renal failure, with limited regeneration of the parent compound. The sulphate metabolite did not accumulate as predicted, possibly because of depletion of inorganic sulphate.
Similar content being viewed by others
References
Clements JA, Critchley JAJH, Prescott LF (1984) The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. Br J Clin Pharmacol 18: 481–485
Forrest JAH, Clements JA, Prescott LF (1982) Clinical pharmacokinetics of paracetamol. Clin Pharmacokinet 7: 93–107
Freeman RM, Richards CJ (1979) Studies on sulphate in end-stage renal disease. Kidney Int 15: 167–175
Hendrix-Treacy S, Wallace SM, Hindmarsh KW, Wyant GM, Danilkewich A (1986) The effect of acetaminophen administration on its disposition and body stores of sulphate. Eur J Clin Pharmacol 30: 273–278
Levy G, Yamada H (1971) Drug biotransformation interactions in man III. Acetaminophen and salicylamide. J Pharm Sci 60: 215–221
Lin JH, Levy G (1981) Sulfate depletion after acetaminophen administration and replenishment by infusion of sodium sulfate or N-acetylcysteine in rats. Biochem Pharmacol 30: 2723–2727
Lin JH, Levy G (1982) Effect of experimental renal failure on sulfate retention and acetaminophen pharmacokinetics in rats. J Pharmacol Exp Ther 221: 80–84
Øie S, Lowenthal DT, Briggs WA, Levy G (1975) Effect of hemodialysis on kinetics of acetaminophen elimination by anephric patients. Clin Pharmacol Ther 18: 680–686
Prescott LF, Speirs GC, Critchley JAJH, Temple RM, Winney RJ (1989) Paracetamol disposition and metabolic kinetics in patients with chronic renal failure. Eur J Clin Pharmacol 36: 291–297
Siegers C-P, Klaassen CD (1984) Biliary excretion of acetaminophen in ureter-ligated rats. Pharmacol 28: 177–180
Verbeeck RK, Branch RA, Wilkinson GR (1981) Drug metabolites in renal failure: pharmacokinetic and clinical implications. Clin Pharmacokinet 6: 329–345
Wagner JG (1975) Fundamentals of clinical pharmacokinetics, Drug Intelligence Publications, Illinois
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Martin, U., Temple, R.M., Winney, R.J. et al. The disposition of paracetamol and the accumulation of its glucuronide and sulphate conjugates during multiple dosing in patients with chronic renal failure. Eur J Clin Pharmacol 41, 43–46 (1991). https://doi.org/10.1007/BF00280104
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00280104